ClinicalImpact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors. 

Taofeek K. Owonikoko, MD, PhD Released: January 21, 2021

Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of advanced RET fusion–positive NSCLC, including monitoring for and managing common adverse events with new-generation, selective RET inhibitors.

Karen L. Reckamp, MD, MS Released: March 16, 2021

Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of metastatic RET-altered thyroid cancer.

Marcia Brose, MD, PhD, FASCO Released: March 16, 2021

Download these slides to review expert insights from a pathologist on best testing practices to identify patients with advanced thyroid cancer and NSCLC eligible for treatment with a RET specific inhibitor.

Laura J. Tafe, MD Released: March 16, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar featuring expert guidance on the optimal management of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Taofeek K. Owonikoko, MD, PhD Released: January 29, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar featuring a molecular pathologist and medical oncologists with expertise in lung and thyroid cancer discussing the latest clinical data on optimal treatment of RET-altered disease with new-generation, selective RET inhibitors.

Marcia Brose, MD, PhD, FASCO Karen L. Reckamp, MD, MS Laura J. Tafe, MD Released: April 13, 2021